Vericel (VCEL) Stock Price, News & Analysis

Company Overview

Vericel Corporation is a commercial-stage biopharmaceutical company focused on cell therapies and advanced treatments for severe injuries and damaged tissue. The company develops and commercializes products designed to support the repair or replacement of tissue that may not heal adequately through conventional treatment.

Vericel’s primary products include MACI, an autologous cell therapy used to repair symptomatic, full-thickness cartilage defects of the knee in adults, and Epicel, a cultured epidermal autograft used for permanent skin replacement in patients with deep dermal or full-thickness burns. Vericel also markets NexoBrid in North America, an enzymatic treatment used to remove nonviable tissue, or eschar, from deep partial-thickness and full-thickness thermal burns.

Based in Cambridge, Massachusetts, Vericel serves the U.S. market and has expanded its activities in North America through commercial partnerships. The company was formerly known as Aastrom Biosciences and adopted the Vericel name in 2014. Its products are administered through hospitals, burn centers, orthopedic practices and other specialized healthcare providers.

Key Stats

• Today's Range: $38.74 to $39.80
• 50-Day Range: $37.87 to $47.61
• 52-Week Range: $28.95 to $49.32
• Volume: 359,339 shs
• Average Volume: 479,084 shs
• Market Capitalization: $2.03 billion
• P/E Ratio: 84.49
• Dividend Yield: N/A
• Price Target: $58.40
• Consensus Rating: Moderate Buy

Vericel Stock Analysis - MarketRank™

Vericel scored higher than 74% of companies evaluated by MarketBeat, and ranked 179th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vericel has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Vericel has a consensus price target of $58.40, representing about 47.1% upside from its current price of $39.71.

Amount of Analyst Coverage

Vericel has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 55.56%

Earnings Growth

Earnings for Vericel are expected to grow by 55.56% in the coming year, from $0.54 to $0.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vericel is 84.49, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vericel is 84.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.

Price to Book Value per Share Ratio

Vericel has a P/B Ratio of 5.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.59% of the float of Vericel has been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 12.13, which indicates bearish sentiment.

Change versus previous month

Short interest in Vericel has recently increased by 15.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vericel does not currently pay a dividend.

Dividend Growth

Vericel does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.21

News Sentiment

Vericel has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Vericel this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $220,050.00 in company stock.

Percentage Held by Insiders

7.60% of the stock of Vericel is held by insiders.

Percentage Held by Institutions

Vericel has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VCEL
• CIK: 887359
• Web: www.vcel.com
• Phone: (617) 588-5555
• Fax: 617-588-5554
• Employees: 398
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vericel: $58.40
• High Price Target: $70.00
• Low Price Target: $46.00
• Potential Upside/Downside: +47.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.47
• Trailing P/E Ratio: 84.49
• Forward P/E Ratio: 73.54
• P/E Growth: N/A
• Net Income: $16.52 million
• Net Margins: 7.91%
• Pretax Margin: 8.19%
• Return on Equity: 6.91%
• Return on Assets: 5.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.04
• Quick Ratio: 4.69

Sales & Book Value

• Annual Sales: $306.30 million
• Price / Sales: 6.64
• Cash Flow: $0.56 per share
• Price / Cash Flow: 71.49
• Book Value: $7.01 per share
• Price / Book: 5.66

Miscellaneous

• Outstanding Shares: 51,207,000
• Free Float: 47,315,000
• Market Cap: $2.03 billion
• Optionable: Optionable
• Beta: 1.04